Evidence‐based comparison of glucagon‐like peptide receptor agonists and sodium–glucose cotransporter 2 inhibitors

Παρόμοια τεκμήρια

• Antihypertensive Effect of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-like Peptide 1 Receptor Agonists
  ανά: Marijana Tadic, κ.ά.
  Έκδοση: (2024-03-01)
• Glucagon-like Peptide-1 Receptor Agonists versus Sodium-Glucose Cotransporter Inhibitors for Treatment of T2DM
  ανά: McKee, Alexis, κ.ά.
  Έκδοση: (2020)
• Review of cardiovascular outcomes trials of sodium – glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists
  ανά: North, Emily J., κ.ά.
  Έκδοση: (2019)
• CORRIGENDUM FOR “Glucagon-like Peptide-1 Receptor Agonists versus Sodium-Glucose Cotransporter Inhibitors for Treatment of T2DM”
  Έκδοση: (2020)
• Erratum to: Glucagon-like Peptide-1 Receptor Agonists versus Sodium-Glucose Cotransporter Inhibitors for Treatment of T2DM
  Έκδοση: (2021)